Hejazi Najmeh, Ghalandari Hamid, Rahmanian Raha, Haghpanah Fatemeh, Makhtoomi Maede, Asadi Amirhossein, Askarpour Moein
Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Students' Research Committee, School of Nutrition and Food Science, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Community Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Clin Nutr ESPEN. 2024 Dec;64:133-143. doi: 10.1016/j.clnesp.2024.09.014. Epub 2024 Sep 28.
Disturbed glycemia and the resulting type 2 diabetes (T2D) are significant health concerns. Various approaches have been examined to improve glycemic control in patients with T2D. Modification of gut microbiome via administering probiotics has been extensively studied. The present study aims to sum up the existing literature which investigated the effect of probiotics on glycemic indices in individuals with T2D in the format of randomized controlled trials (RCTs).
Online medical databases (PubMed, Scopus, and Web of Science) were searched from inception to January 2024. Eligible studies were included using pre-defined inclusion and exclusion criteria. Outcome variables included fasting blood sugar (FBS), insulin, hemoglobin A1c (HbA1c), and homeostatic model of insulin resistance (HOMA-IR). Weighted mean differences (WMDs) were estimated. Subgroup and dose-response analyses were conducted. P-values <0.05 were considered as statistically significant.
Out of 5636 records retrieved by the initial search, thirty-two RCTs were included in the final analyses. Supplementation with probiotics was observed to significantly improve indices of glycemic control; including FBS (WMD: -13.27 mg/dl; 95 % CI: -18.31, -8.22), HbA1c (WMD: -0.44 %; 95 % CI: -0.59, -0.28), insulin (WMD: -1.33 μIU/ml; 95 % CI: -2.57, -0.08), and HOMA-IR (WMD: -0.95; 95 % CI: -1.71, -0.18). Dose-response analysis revealed that increased duration of intervention results in a larger reduction only in FBS.
Supplementation with probiotics seems to improve indices of glycemic control. Nonetheless, taken into account the notable heterogeneity (with regard to dosage, duration, and the species/strains used) between the included studies and low quality of evidence, caution must be considered, especially when long-term clinical implications are intended.
血糖紊乱及由此导致的2型糖尿病(T2D)是重大的健康问题。人们已经研究了各种改善T2D患者血糖控制的方法。通过施用益生菌来改变肠道微生物群已得到广泛研究。本研究旨在以随机对照试验(RCT)的形式总结现有文献,这些文献调查了益生菌对T2D个体血糖指标的影响。
检索了从创建到2024年1月的在线医学数据库(PubMed、Scopus和Web of Science)。使用预先定义的纳入和排除标准纳入符合条件的研究。结果变量包括空腹血糖(FBS)、胰岛素、糖化血红蛋白(HbA1c)和胰岛素抵抗稳态模型(HOMA-IR)。估计加权平均差(WMDs)。进行亚组分析和剂量反应分析。P值<0.05被认为具有统计学意义。
在初步检索获得的5636条记录中,最终分析纳入了32项RCT。观察到补充益生菌可显著改善血糖控制指标;包括FBS(WMD:-13.27mg/dl;95%CI:-18.31,-8.22)、HbA1c(WMD:-0.44%;95%CI:-0.59,-0.28)、胰岛素(WMD:-1.33μIU/ml;95%CI:-2.57,-0.08)和HOMA-IR(WMD:-0.95;95%CI:-1.71,-0.18)。剂量反应分析显示,干预持续时间增加仅导致FBS更大幅度的降低。
补充益生菌似乎可改善血糖控制指标。然而,考虑到纳入研究之间在剂量、持续时间以及所用菌种/菌株方面存在显著异质性,且证据质量较低,必须谨慎对待,尤其是在考虑长期临床影响时。